Author:
Koshmanova A.N., ,Maksimov M.L.,
Abstract
Cefepime/sulbactam is a combined antibiotic with a wide spectrum of antimicrobial activity, including cefepime, the fourth-generation cephalosporin, and sulbactam, the beta-lactamase inhibitor, in a 1:1 ratio. Cefepime/sulbactam has a bactericidal effect: it causes a disorder in cell wall synthesis due to blockade of transpeptidase and a disorder in the formation of cross-links in peptidoglycan [1]. Today, the problem of antibiotic resistance is growing rapidly. In the WHO list, a critically high level of priority for the development of new antibiotics is occupied by infections caused by ESBL-producing gram-negative bacteria that are resistant to cephalosporins, as well as carbapenem-resistant Enterobacterales, Acinetobacter baumannii and Pseudomonas aeruginosa [2]. Infections caused by multiresistant bacteria are characterized by a longer course, require prolonged hospitalization, are very difficult to treat with modern antibacterial drugs, and increase the risk of death [3]. In this regard, a deeper study of the action of individual antibacterial drugs and their combination with β-lactamase inhibitors in the treatment of diseases caused by multiresistant microorganisms is crucial.
Publisher
PANORAMA Publishing House
Reference8 articles.
1. 1. Farmakologiia [Pharmacology]: textbook / D. A. Kharkevich. - 12th ed., revised and expanded. - M.: GEO¬TAR-Media, 2017; 567-586. (In Russ.)
2. 2. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new an-tibiotics. WHO, February 27, 2017.
3. 3. Suvorova M. P., Bykov A. O., Iakovlev S. V., Sychev I. N., Mirzakhamidova S. S., Burmistrova E. N. Effektivnost, bezopasnost i risk selektsii rezistentnoi mikroflory pri lechenii tiazhelykh infektsii v statsionare preparatom s deistvui¬ushchimi veshchestvami tsefepim+ [sulbaktam] po sravneniiu s preparatami karbapenemov [Efficacy, safety and risk of selection of resistant microflora in the treatment of severe infections in a hospital with the drug with the active ingredients cefepime + [sulbactam] compared with carbapenems]. Anesteziologiia i reanima¬tologiia [Anesthesiology and Resuscitation]. 2020; 3:59-69. (In Russ.)
4. 4. Iakovlev S. V., Suvorova M. P., Bykov A. O. Tsefepim/sulbaktam - novyi innovatsionnyi otechestvennyi antibiotik dlia lecheniia tiazhelykh infektsii v statsionare i realizatsii karbapenem-zameshchaiushchei strategii sder-zhivaniia antibiotikorezistentnosti [Cefepime/sulbactam is a new innovative domestic antibiotic for the treatment of severe infections in a hospital and the implementation of a carbapenem-substituting strate¬gy to contain antibiotic resistance]. Antibiotiki i khimioter. [Antibiotics and Chemo]. 2021; 66:3-4:82-98. (In Russ.)
5. 5. An agent for the treatment of infectious diseases caused by multi-resistant bacteria. Patent for invention, No. 2377985, Russia, publication year 2010, application No. 2006145753/15. (In Russ.)